EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

Funding for this study was provided by the National Office of Public Health Genomics, Centers for Disease Control and Prevention, through a contract (200-2003-01396-0128) with McK- ing Consulting Corporation, Inc. We thank the members of the Technical Evaluation Panel, including EGAPP Working Group members Celia I. Kaye, MD, University of Colorado at Denver and Health Sciences Center; Margaret Piper, PhD, MPH, Blue Cross/Blue Shield Association Technology Evaluation Center; James E. Haddow, MD, Women and Infants Hospital, The Warren Alpert School of Medicine at Brown University; Sue Richards, PhD, Oregon Health and Science University; and Linda A. Bradley, PhD, National Office of Public Health Genomics, CDC, who provided guidance and comments on drafts of this manuscript. We also thank Scott D. Grosse, PhD, National Center on Birth Defects and Developmental Disabilities, CDC and Mercy Mvundura, PhD, National Office of Public Health Genomics, CDC, for their helpful comments regarding the economic analyses.